Literature DB >> 33824460

Triptolide protects against white matter injury induced by chronic cerebral hypoperfusion in mice.

Yu-Shan Wan1, Yi You1, Qian-Yun Ding1,2, Yi-Xin Xu1, Han Chen1, Rong-Rong Wang3, Yu-Wen Huang1, Zhong Chen1,2, Wei-Wei Hu4, Lei Jiang5.   

Abstract

White matter injury is the major pathological alteration of subcortical ischemic vascular dementia (SIVD) caused by chronic cerebral hypoperfusion. It is characterized by progressive demyelination, apoptosis of oligodendrocytes and microglial activation, which leads to impairment of cognitive function. Triptolide exhibits a variety of pharmacological activities including anti-inflammation, immunosuppression and antitumor, etc. In this study, we investigated the effects of triptolide on white matter injury and cognitive impairments in mice with chronic cerebral hypoperfusion induced by the right unilateral common carotid artery occlusion (rUCCAO). We showed that triptolide administration alleviated the demyelination, axonal injury, and oligodendrocyte loss in the mice. Triptolide also improved cognitive function in novel object recognition test and Morris water maze test. In primary oligodendrocytes following oxygen-glucose deprivation (OGD), application of triptolide (0.001-0.1 nM) exerted concentration-dependent protection. We revealed that the protective effect of triptolide resulted from its inhibition of oligodendrocyte apoptosis via increasing the phosphorylation of the Src/Akt/GSK3β pathway. Moreover, triptolide suppressed microglial activation and proinflammatory cytokines expression after chronic cerebral hypoperfusion in mice and in BV2 microglial cells following OGD, which also contributing to its alleviation of white matter injury. Importantly, mice received triptolide at the dose of 20 μg·kg-1·d-1 did not show hepatotoxicity and nephrotoxicity even after chronic treatment. Thus, our results highlight that triptolide alleviates whiter matter injury induced by chronic cerebral hypoperfusion through direct protection against oligodendrocyte apoptosis and indirect protection by inhibition of microglial inflammation. Triptolide may have novel indication in clinic such as the treatment of chronic cerebral hypoperfusion-induced SIVD.
© 2021. The Author(s), under exclusive licence to CPS and SIMM.

Entities:  

Keywords:  chronic cerebral hypoperfusion; microglial activation; oligodendrocyte; right unilateral common carotid artery occlusion (rUCCAO); triptolide; white matter injury

Mesh:

Substances:

Year:  2021        PMID: 33824460      PMCID: PMC8724323          DOI: 10.1038/s41401-021-00637-0

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  47 in total

Review 1.  Vascular cognitive impairment.

Authors:  Ola A Selnes; Harry V Vinters
Journal:  Nat Clin Pract Neurol       Date:  2006-10

Review 2.  Toxicity of triptolide and the molecular mechanisms involved.

Authors:  Chen Xi; Shaojun Peng; Zhengping Wu; Qingping Zhou; Jie Zhou
Journal:  Biomed Pharmacother       Date:  2017-04-10       Impact factor: 6.529

Review 3.  Therapeutic strategies for Parkinson's disease: the ancient meets the future--traditional Chinese herbal medicine, electroacupuncture, gene therapy and stem cells.

Authors:  Xuan Wang; Xi-Bin Liang; Feng-Qiao Li; Hui-Fang Zhou; Xian-Yu Liu; Jian-Jun Wang; Xiao-Min Wang
Journal:  Neurochem Res       Date:  2008-04-11       Impact factor: 3.996

4.  Anti-inflammatory and neuroprotective effects of triptolide on traumatic brain injury in rats.

Authors:  Hung-Fu Lee; Tzong-Shyuan Lee; Yu Ru Kou
Journal:  Respir Physiol Neurobiol       Date:  2012-02-17       Impact factor: 1.931

Review 5.  Triptolide and Its Derivatives as Cancer Therapies.

Authors:  Pawan Noel; Daniel D Von Hoff; Ashok K Saluja; Mohana Velagapudi; Erkut Borazanci; Haiyong Han
Journal:  Trends Pharmacol Sci       Date:  2019-04-08       Impact factor: 14.819

6.  Intrathecal administration of triptolide, a T lymphocyte inhibitor, attenuates chronic constriction injury-induced neuropathic pain in rats.

Authors:  Jin-Yu Hu; Chang-Lin Li; Ying-Wei Wang
Journal:  Brain Res       Date:  2011-12-04       Impact factor: 3.252

Review 7.  Triptolide with potential medicinal value for diseases of the central nervous system.

Authors:  Yan Zheng; Wen-Jing Zhang; Xiao-Min Wang
Journal:  CNS Neurosci Ther       Date:  2012-12-18       Impact factor: 5.243

Review 8.  Triptolide: progress on research in pharmacodynamics and toxicology.

Authors:  Xiao-Jiaoyang Li; Zhen-Zhou Jiang; Lu-yong Zhang
Journal:  J Ethnopharmacol       Date:  2014-06-13       Impact factor: 4.360

9.  Triptolide up-regulates metabotropic glutamate receptor 5 to inhibit microglia activation in the lipopolysaccharide-induced model of Parkinson's disease.

Authors:  Yi-Ying Huang; Qian Zhang; Jian-Nan Zhang; Ya-Nan Zhang; Li Gu; Hui-Min Yang; Ning Xia; Xiao-Min Wang; Hong Zhang
Journal:  Brain Behav Immun       Date:  2018-04-09       Impact factor: 7.217

Review 10.  Application and Mechanisms of Triptolide in the Treatment of Inflammatory Diseases-A Review.

Authors:  Kai Yuan; Xiaohong Li; Qingyi Lu; Qingqing Zhu; Haixu Jiang; Ting Wang; Guangrui Huang; Anlong Xu
Journal:  Front Pharmacol       Date:  2019-12-06       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.